sotrastaurin
Small moleculeexperimental
Clinical trial activity
20 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
12
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2006 (NCT00409929)
Timeline
Indications
Studied for
- Colitis, Ulcerative · Phase 2
- Healthy Volunteers · Phase 1
- Kidney Transplantation · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Prolymphocytic · Phase 2
- Liver Transplantation · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 2
- Melanoma · Phase 1/Phase 2
- Panuveitis · Phase 2
- Psoriasis · Phase 2
- Uveitis · Phase 2
- Uveitis, Posterior · Phase 2
Mechanism of action
- Protein kinase C (PKC)INHIBITOR
Protein kinase C (PKC) inhibitor
- Serine/threonine-protein kinase D3 (PRKD3) ↗
- Protein kinase C iota type (PRKCI) ↗
- Protein kinase C alpha type (PRKCA) ↗
- Protein kinase C gamma type (PRKCG) ↗
- Protein kinase C delta type (PRKCD) ↗
- Protein kinase C beta type (PRKCB) ↗
- Protein kinase C zeta type (PRKCZ) ↗
- Protein kinase C epsilon type (PRKCE) ↗
- Protein kinase C eta type (PRKCH) ↗
- Serine/threonine-protein kinase D1 (PRKD1) ↗
- Protein kinase C theta type (PRKCQ) ↗
- Protein kinase C zeta
- Protein kinase C epsilon
- Protein kinase C gamma
- Protein kinase C nu
- Protein kinase C iota
- Protein kinase C mu
- Protein kinase C eta
- Protein kinase C alpha
- Protein kinase C beta
- Protein kinase C delta
- Protein kinase C theta
- Protein kinase C, PKC; classical/novel
- PKC alpha and beta-2
- Protein kinase C iota type/zeta type
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1- Mol. weight
- 438.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL565612 ↗
- ChEMBLCHEMBL2105655 ↗
Also known as
- aeb071
- aeb071
- aeb071
- aeb071
- aeb-071
- aeb-071
- nvp-aeb071
- nvp-aeb071
- sotrastaurin
- sotrastaurin
- sotrastaurin
- sotrastaurin
- sotrastaurin
- sotrastaurin acetate
- sotrastaurin acetate
- sotrastaurin acetate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02285244 | Phase 2 | Mar 12, 2015 | Novartis, Ohio State University |
| NCT02273219 | Phase 1 | Nov 1, 2014 | Columbia University |
| NCT01854606 | Phase 1 | Dec 5, 2013 | Novartis |
| NCT01801358 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2013 | Array BioPharma |
| NCT01430416 | Phase 1 | Dec 20, 2011 | Novartis |
| NCT01402440 | Phase 1 | Nov 1, 2011 | Novartis |
| NCT01128335 | Phase 2 | Apr 1, 2010 | Novartis |
| NCT00572585 | Phase 2 | Apr 1, 2010 | Novartis |
| NCT01064791 | Phase 2 | Dec 1, 2009 | Novartis |
| NCT01594255 | Phase 1 | Jul 1, 2009 | Novartis |
| NCT00885196 | Phase 2 | Apr 1, 2009 | Novartis |
| NCT00820911 | Phase 2 | Sep 1, 2008 | Novartis |
| NCT00615693 | Phase 2 | Jul 1, 2008 | Novartis |
| NCT00555789 | Phase 2 | Oct 1, 2007 | Novartis |
| NCT00545259 | Phase 1 | Oct 1, 2007 | Novartis |
| NCT00504543 | Phase 2 | Jul 1, 2007 | Novartis |
| NCT00492869 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2007 | Novartis |
| NCT00403416 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2006 | Novartis |
| NCT00416546 | Phase 1 | Oct 1, 2006 | Novartis |
| NCT00409929 | Phase 1 | Jun 1, 2006 | Novartis |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 18 | 17 | 2 | 2006 |
| Array BioPharma | For profit | 1 | 1 | 1 | 2013 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2015 |
4 organizations
Page 1 / 1